Azenta, Inc. income statement
In fiscal 2025, Azenta, Inc. reported revenue of $594m, up 3.6% on the year before, operating income of −$26.8m (a -4.5% margin) and net income of −$55.8m, or −$1.22 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.
Income statement
| Fiscal year | 2009Sept 2009 | 2010Sept 2010 | 2011Sept 2011 | 2012Sept 2012 | 2013Sept 2013 | 2014Sept 2014 | 2015Sept 2015 | 2016Sept 2016 | 2017Sept 2017 | 2018Sept 2018 | 2019Sept 2019 | 2020Sept 2020 | 2021Sept 2021 | 2022Sept 2022 | 2023Sept 2023 | 2024Sept 2024 | 2025Sept 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 219 | 593 | 688 | 489 | 422 | 483 | 553 | 434 | 527 | 632 | 334 | 389 | 514 | 555 | 551 | 573 | 594 | 614 |
| Cost of revenue | 225 | 427 | 465 | 330 | 290 | 316 | 364 | 362 | 425 | 385 | 200 | 216 | 270 | 300 | 312 | 319 | 324 | 343 |
| Gross profit | −6 | 166 | 223 | 159 | 132 | 167 | 189 | 157 | 199 | 246 | 135 | 172 | 244 | 256 | 239 | 255 | 270 | 270 |
| Research and development | 32 | 31 | 40 | 45 | 46 | 53 | 52 | 44 | 40 | 47 | 17 | 18 | 22 | 28 | 32 | 32 | 30 | 36 |
| Selling, general and administrative | 91 | 86 | 103 | 98 | 97 | 111 | 115 | 119 | 142 | 167 | 163 | 190 | 252 | 251 | 264 | 263 | 262 | 257 |
| Operating income | −228 | 47 | 80 | 2 | −17 | −3 | 17 | −17 | 14 | 31 | −47 | −37 | −31 | −25 | −61 | −51 | −27 | −175 |
| Interest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10 | 22 | 3 | 2 | 5 | — | — | — | — |
| Income before tax | −227 | 56 | 128 | 4 | −15 | −2 | 18 | −18 | 15 | 20 | −84 | −40 | −49 | −10 | −20 | −19 | −7 | −152 |
| Income tax | 1 | −3 | 2 | −126 | −5 | −2 | 3 | 66 | 3 | −47 | −23 | −14 | −20 | 1 | −12 | 5 | −32 | −40 |
| Net income | −228 | 60 | 130 | 137 | −2 | 31 | 14 | −69 | 63 | 117 | 437 | 65 | 111 | 2,133 | −15 | −165 | −56 | −123 |
| Diluted EPS | −$3.62 | $0.93 | $2.01 | $2.08 | −$0.03 | $0.46 | $0.21 | −$1.01 | $0.89 | $1.64 | $6.04 | $0.88 | $1.49 | $28.48 | −$0.22 | −$3.10 | −$1.22 | −$2.68 |
| Diluted shares (average) | 63m | 64m | 65m | 66m | 66m | 68m | 69m | 69m | 70m | 71m | 72m | 74m | 74m | 75m | 66m | 53m | 46m | 46m |
| EBITDA | −202 | 65 | 97 | 23 | 7 | 21 | 42 | 11 | 42 | 69 | 7 | 29 | 34 | 29 | 24 | 39 | 34 | −120 |
| Quarter | 2024 Q4Sept 2024 | 2025 Q1Dec 2024 | 2025 Q2Mar 2025 | 2025 Q3Jun 2025 | 2025 Q4Sept 2025 | 2026 Q1Dec 2025 | 2026 Q2Mar 2026 | 2026 Q3Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 151 | 147 | 143 | 144 | 159 | 149 | 145 | 161 |
| Cost of revenue | 82 | 79 | 81 | 77 | 87 | 85 | 83 | 89 |
| Gross profit | 68 | 69 | 63 | 66 | 72 | 64 | 62 | 72 |
| Research and development | 8 | 7 | 8 | 7 | 8 | 9 | 9 | 9 |
| Selling, general and administrative | 65 | 70 | 70 | 60 | 62 | 61 | 68 | 67 |
| Operating income | −5 | −9 | −18 | −2 | 2 | −7 | −166 | −4 |
| Provision for credit losses | — | 1 | 3 | −0 | — | −0 | 2 | −1 |
| Income before tax | 0 | −3 | −13 | 2 | 6 | −2 | −157 | 1 |
| Income tax | 2 | 4 | 7 | 3 | −45 | 3 | −0 | 2 |
| Net income | −7 | −11 | −48 | −48 | 51 | −15 | −161 | 2 |
| Diluted EPS | −$0.14 | −$0.25 | −$1.04 | −$1.05 | $1.11 | −$0.34 | −$3.49 | $0.05 |
| EBITDA | 19 | 9 | −4 | 13 | 16 | 6 | −152 | 9 |
Compare with peers
- 10x Genomics, Inc. income statement
- Veracyte, Inc. income statement
- Neogenomics Inc income statement
- Repligen Corp income statement
- Twist Bioscience Corp income statement
Head to head: AZTA vs TXGAZTA vs VCYTAZTA vs NEOAZTA vs RGEN
More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies